Acro Biomedical (ACBM) FCF Margin (2017 - 2022)

Acro Biomedical has reported FCF Margin for 6 years, with the latest figure at 2.94% in Q4 2022.

• On a quarterly basis, FCF Margin rose 718.0% year-over-year to 2.94% in Q4 2022; TTM through Sep 2023 was 3.72%, a 1830.0% increase from a year earlier, with the FY2022 full-year figure at 22.4%, down 4739.0% from the prior year.
• FCF Margin was 2.94% for Q4 2022 at Acro Biomedical, down from 87.82% in the prior quarter.
• The five-year high for FCF Margin was 87.82% in Q1 2022, with the low at 23.3% in Q2 2018.
• Average FCF Margin over 5 years is 16.13%, with a median of 0.17% recorded in 2018.
• The sharpest annual moves came in 2021 and 2022: FCF Margin plunged 464 bps in 2021, then jumped 9624 bps in 2022.
• Over 5 years, FCF Margin stood at 12.88% in 2018, then soared by 40 bps to 18.05% in 2019, then sank by 121 bps to 3.78% in 2020, then plunged by 168 bps to 10.12% in 2021, then soared by 71 bps to 2.94% in 2022.
• The last three FCF Margin figures came in at 2.94% (Q4 2022), 87.82% (Q1 2022), and 10.12% (Q4 2021), per Business Quant data.